Greenphire and Oracle to Work Together
News Jun 25, 2013
Greenphire has announced a relationship with Oracle Health Sciences. Oracle and Greenphire are integrating their respective product suites to enable their clients to streamline and automate processes from trial planning and budgeting, all the way through data capture to executing payments to clinical sites and patients, while providing real-time, strategically valuable reporting and analytics.
The first initiative will be the integration of Greenphire’s global payment platform, eClinicalGPS, with Oracle’s electronic data capture (EDC) solutions, Oracle Health Sciences InForm and Oracle Remote Data Capture (RDC).
This integration will help ensure that clients have quick product implementations without relying on internal development and staffing.
Data sharing between EDC and payment technologies will enable a virtually seamless transition between the collection and capture of clinical data and the accurate execution of payments.
Greenphire and Oracle are currently working with three joint clients including two top 10 global biopharmaceutical clients and a fast growing biotechnology client.
“Clinical trial sponsors and their CRO partners are focused on improving productivity and efficiency across their clinical programs - including study set up, recruitment, data collection and analysis, as well as the administration of and payments to research sites and participants. Integrations between the Oracle and Greenphire product suites can help biopharmaceutical companies and CROs achieve new levels of efficiency and deliver powerful analytics that support continuous improvement. This will enable companies to re-direct freed up resources to discovery and development initiatives,” said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences.
“Greenphire is committed to continually finding ways to increase efficiencies in clinical research processes and to drive value and cost savings for our clients,” said Greenphire Founder & CEO Sam Whitaker.
Whitaker continued, “Our relationship with Oracle is a tremendous opportunity to find innovative ways to streamline existing processes and to ultimately simplify financial planning and management of clinical trials, by working with a company that offers world-class e-clinical solutions.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Bone Cancer Drug Targets Tumors, Spares Other OrgansNews
A study led by The University of Texas MD Anderson Cancer Center found a drug known as bone metastasis-targeting peptidomimetic (BMTP-11) has potential as a new therapeutic strategy for this devastating illness.READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018